Business / Finance

RSS

Neurodyn acquires all assets related to new drug candidate Memogain from Galantos Pharma

Neurodyn Inc. announced today that it has acquired from Galantos Pharma GmbH, Mainz, Germany all assets related to their Alzheimer's prescription drug candidate - Memogain. Memogain has completed an extensive preclinical development program and is ready to proceed into Phase 1 clinical trials in late 2013. The terms of the acquisition were not disclosed.

5 Sep 2013

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Affinium Pharmaceuticals announced today that it has initiated dosing in a Phase 1 intravenous clinical trial of its new antibiotic prodrug, AFN-1720. AFN-1720 is the prodrug of the active drug, AFN-1252.

5 Sep 2013

Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Sanofi US and POZEN Inc. announced the signing of an exclusive license agreement for the commercialization of POZEN's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor, and enteric-coated aspirin in a single tablet ("PA"), PA8140 and PA32540.

5 Sep 2013

Accelrys Buys Chemsw In Deal Worth Up To $17.3M

...

4 Sep 2013

Repligen Earns $1M Pfizer Milestone Payment

...

4 Sep 2013

Revived Genvec Withdraws Dissolution Plan; New CEO Named

...

4 Sep 2013

Ultragenyx, Kyowa Hakko Kirin To Develop Rare Bone Disease-Fighting Mab

...

4 Sep 2013

Taconic To Promote And Sell Medicyte Hepatocyte Products

...

4 Sep 2013

Rochester Medical enters into definitive merger agreement with C. R. Bard

Rochester Medical Corporation today announced it has entered into a definitive merger agreement with C. R. Bard, Inc. at a price of $20 per share, or approximately $262 million in the aggregate.

4 Sep 2013

Cangene Signs Up To $77M Contract Extension With CDC

...

3 Sep 2013

Enanta Gets Additional $9.2M Toward Biodefense Antibiotic Development

...

3 Sep 2013

Baxter, Coherus Ink Biosimilar Collaboration Worth Up To $246M

...

3 Sep 2013

Cangene Inks Up To $77M Contract Extension With CDC

...

3 Sep 2013

Viralytics releases financial results for 2013

Viralytics Limited (ASX:VLA, OTCQX:VRACY) has released its financial results for the year ended 30 June 2013.

3 Sep 2013

Sanomedics completes acquisition of Prime Time Medical

Sanomedics International Holdings, Inc., a medical technology holding company that focuses on game-changing products, services and ideas, today announced that it has completed the previously announced acquisition of Prime Time Medical, Inc., of Largo, Florida for a total purchase price of $3,100,000, effective August 30, 2013.

3 Sep 2013

Cambridge Epigenetix’s pioneering TrueMethyl™ kit proves successful in beta trial

Cambridge Epigenetix Ltd. (CEGX), a leader in epigenetics tools innovation, today published the results of a successful beta trial evaluating their pioneering TrueMethyl™ oxidative bisulfite sequencing (oxBS-Seq) technology.

3 Sep 2013

Acacia Pharma raises $23.5 million in Series B financing

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces it has raised £15 million (~$23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S.

3 Sep 2013

Covalon completes non-brokered private placement comprised of 750 units

Covalon Technologies Ltd. (the "Company" or "Covalon"), an advanced medical technologies company, today announced that further to its press release of August 16, 2013, it has completed, subject to final approval of the TSX Venture Exchange, a non-brokered private placement comprised of 750 units (the "Units") at a price of $1,000 per Unit for gross proceeds of $750,000. Each Unit consists of $1,000 principal amount of 12% senior secured convertible debenture (the "Debentures" and each a "Debenture") and 6,451 warrants (each, a "Warrant").

31 Aug 2013

Okana acquires North American product rights for FACTIVE tablets from Merus Labs International

Okana Ventures Inc. is pleased to announce the acquisition of the North American product rights for FACTIVE® (Gemifloxacin Mesylate) tablets from Merus Labs International for approximately US$3.4 million.

31 Aug 2013

LNHASC selects Clinical Outcomes Management Systems Interactive as Preferred Partner

The Louisiana Nursing Home Association Service Corporation (LNHASC) has chosen COMS Interactive, LLC (Clinical Outcomes Management Systems or COMS) as a Preferred Partner.

31 Aug 2013